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ARTICLE
Minimally disruptive optical control of protein
tyrosine phosphatase 1B
Akarawin Hongdusit1, Peter H. Zwart2, Banumathi Sankaran2 & Jerome M. Fox 1*
Protein tyrosine phosphatases regulate a myriad of essential subcellular signaling events, yet
they remain difficult to study in their native biophysical context. Here we develop a minimally
disruptive optical approach to control protein tyrosine phosphatase 1B (PTP1B)—an important
regulator of receptor tyrosine kinases and a therapeutic target for the treatment of diabetes,
obesity, and cancer—and we use that approach to probe the intracellular function of this
enzyme. Our conservative architecture for photocontrol, which consists of a protein-based
light switch fused to an allosteric regulatory element, preserves the native structure, activity,
and subcellular localization of PTP1B, affords changes in activity that match those elicited by
post-translational modifications inside the cell, and permits experimental analyses of the
molecular basis of optical modulation. Findings indicate, most strikingly, that small changes in
the activity of PTP1B can cause large shifts in the phosphorylation states of its regulatory
targets.
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The enzymatic phosphorylation of tyrosine residues is cen-trally important to cellular function. It controls the loca-tion and timing of cellular differentiation, movement,
proliferation, and death1–4; its misregulation can cause cancer,
diabetes, and neurodegenerative diseases, among other dis-
orders5–7. Methods to control the activity of phosphorylation-
regulating enzymes without interfering with their native structure
or cellular organization could, thus, enable detailed analyses
of the mechanisms by which cells process essential chemical
signals8,9.
Optogenetic actuators—genetically encoded proteins that
undergo light-induced changes in conformation—provide a
powerful means of controlling enzyme activity over time and
space. As protein fusion partners, they have enabled optical
manipulation of biomolecular transport, binding, and catalysis
with millisecond and submicron resolution10,11. Common stra-
tegies to integrate optogenetic actuators into enzymes include (i)
attachment near an active site, where they control substrate
access12,13, (ii) insertion within a catalytic domain, where they
afford activity-modulating structural distortions14, and (iii) fusion
to N- or C-termini, where they direct subcellular localization15 or
guide domain assembly16. These approaches have generated
powerful tools for stimulating phosphorylation-mediated signal-
ing networks; unfortunately, their reliance on disruptive struc-
tural modifications has tended to limit their use in biochemical
studies of native regulatory effects, for example, spatially depen-
dent protein–protein interactions or, more notably, shifts in
activity that match, rather than artificially exceed, those caused by
post-translational modifications of an enzyme under study.
Protein tyrosine phosphatase 1B (PTP1B) is an important
regulatory enzyme for which minimally disruptive architectures
for photocontrol could prove particularly informative. This
enzyme, which catalyzes the hydrolytic dephosphorylation of
tyrosine residues, helps regulate insulin, leptin, and epidermal
growth factor signaling and participates in a diverse set of spa-
tiotemporally complex signaling processes17. PTP1B has two
intriguing biophysical traits that make it particularly amenable to
optogenetic study: (i) Its catalytically essential WPD loop
undergoes cyclic, open-and-close motions that control the rate of
phosphotyrosine hydrolysis at the active site18, and its C-terminal
α7 helix modulates these motions through an allosteric network
that extends over 25Å across the protein (Fig. 1a). An archi-
tecture for photocontrol that makes use of this network could
afford changes in activity that preserve interactions between
PTP1B and its regulatory targets. (ii) PTP1B undergoes several
post-translational modifications outside of its active site that
cause modest, yet physiologically influential shifts in its activity
(i.e., 1.7–3.1-fold19,20; Supplementary Table 1). An optogenetic
construct that affords similar changes in activity could help
determine whether or not they—rather than the specific post-
translational modifications that cause them—are sufficient to
influence cellular physiology.
In this study, we used a protein-based light switch to place the
native allosteric regulatory system of PTP1B under optical con-
trol. This conservative optogenetic design preserved the native
structure and subcellular localization of PTP1B, permitted
changes in activity that match those caused by post-translational
modifications inside the cell and, when paired with a FRET-based
biosensor, enabled spatiotemporal control and measurement of
intracellular PTP1B activity. An optogenetic analysis carried out
with this system showed that small, transient changes in PTP1B
activity can cause large shifts in insulin receptor (IR) phosphor-
ylation. The optogenetic tools developed in this study thus
complement existing methods for studying protein tyrosine
kinases (PTKs)—which, unlike PTPs, possess many light-sensitive
analogs and FRET-based biosensors21,22—and, more broadly,
demonstrate an optogenetic approach for studying regulatory
enzymes in their native biophysical context.
Results
Allosteric photocontrol of PTP1B. We sought to place PTP1B
under optical control by using LOV2, the light-sensitive domain
from phototropin 1 of Avena sativa, to toggle the conformation of
its α7 helix. LOV2 derives its optical activity from a noncovalently
bound flavin mononucleotide (FMN) that, when exposed to blue
light, forms an intermolecular carbon-sulfur bond that destabi-
lizes the N- and C-terminal helices of the protein (Fig. 1a)23. We
hypothesized that attachment of the N-terminal A’α helix of
LOV2 to the C-terminal α7 helix of PTP1B would couple (i) light-
induced unwinding of the A’α helix to (ii) destabilization of the
α7 helix and disruption of WPD loop motions (Fig. 1b). To our
satisfaction, several PTP1B-LOV2 chimeras—each generated by
fusing the A’α and α7 helices at a different crossover point in a
primary sequence alignment—exhibited light-dependent catalytic
activity on 4-methylumbelliferyl phosphate (4MUP; Fig. 1c).
Fusion of the Jα helix of LOV2 to the N-terminus of PTP1B, by
contrast, did not confer photosensitivity (Supplementary Figs. 1a,
b), a result consistent with the large distance between its N-
terminus and active site (Fig. 1a).
To enhance the dynamic range (DR=Vo-dark/Vo-light) of our
most light-sensitive chimera (i.e., construct 7, where DR= 1.9), we
used two approaches: First, we attempted to improve communica-
tion between the LOV2 and PTP1B domains by reducing the
length of the linker between them; similar changes have improved
photoswitching in other light-sensitive fusions24. Unfortunately,
shorter linkers (which, through residue deletions, could also alter
the phases of the fused helices) tended to reduce DR; we chose one
variant with an unaltered DR—chimera 7.1—for further optimiza-
tion. Next, we attempted to increase the stability of the dark state
over the light state by adding stabilizing mutations to flexible
helices. (For the Jα and A’α helices, we used established stabilizing
mutaitons23,25; for α7, we replaced solvent-exposed residues with
alanine, which has a high helix propensity26). Stabilizing mutations
in the Jα helix have amplified DRs of previous LOV2 fusions25,27.
Intriguingly, for our chimeras, mutations in the Jα helix improved
activity, but reduced photosensitivity; several mutations in the A’α
and α7 helices, by contrast, increased the DR (Fig. 1c). Overall, the
effects of amino acid substitutions in these two helices were non-
additive and reached a maximum DR of 2.2 on 4MUP. We chose
a single high-DR chimera—7.1(T406A), termed PTP1BPS—for
further study.
We assessed the structural integrity of the PTP1B domain
within PTP1BPS by using X-ray crystallography to examine its
dark-state conformation. Intriguingly, although crystals of
PTP1BPS were yellow and turned clear when exposed to blue
light—a behavior indicative of the presence of LOV212,28—
diffraction data permitted placement and refinement of only
PTP1B (Supplementary Figs. 2 and 3). Detection of LOV2 was
likely impeded by two interrelated crystallographic features: (i) a
disordered α7 helix, which is unresolvable in apo structures of
PTP1B29, and (ii) variability in the orientation of LOV2 within
the crystal lattice (Supplementary Note 1). Despite this structural
disorder, aligned catalytic domains of PTP1BPS and wild-type
PTP1B had a root-mean-square deviation of 0.30Å (Fig. 1d).
Crystallographic results, thus, suggest that LOV2 does not alter
the native conformation of the catalytic domain of PTP1B.
We explored the mechanism of photomodulation by using
kinetic assays to examine the influence of LOV2 on PTP1B-
mediated catalysis. In brief, we measured the activity of PTP1BPS
on p-nitrophenyl-phosphate (pNPP) in the presence and absence
of blue light (455 nm), and we used the initial rates to construct
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dark- and light-state Michaelis–Menten curves (Fig. 1e). These
curves indicate that blue light reduces kcat by 2.5-fold but leaves
Km unaltered. Data collected under repeated illumination, in turn,
shows that changes in kcat are reversible (Supplementary Fig. 4c).
The isolated influence of LOV2 on kcat indicates that this
photoswitch does not interfere with substrate binding and,
importantly, is consistent with a mechanism in which LOV2
allosterically modulates WPD loop motions, which control the
rate of hydrolysis18.
To assess the maximum achievable DR for our system, we
removed the α7 helix of PTP1B; that is, we used an α7-less variant
as a model for a maximally photoswitched form of the enzyme.
Intriguingly, helix removal lowered kcat by 2.9-fold, suggesting
that PTP1BPS has a DR that is 85% of the maximum value for a
photoswitch that inhibits catalytic activity by unwinding the α7
helix (Supplementary Figs. 4a, b). Importantly, this DR is within
the range of DRs of previously developed light-sensitive signaling
enzymes used to elicit physiologically relevant cellular responses
to optical stimuli (DRs ~1.7–1012,30; Supplementary Table 8) and
matches physiologically influential changes in activity caused by
post-translational modifications of PTP1B that occur outside of
its active site (i.e., phosphorylation, proteolysis, and sumoylation,
which reduce/enhance PTP1B activity by 1.7–3.1-fold19,20;
Supplementary Table 1).
We hypothesized that an optogenetic system that exerts allosteric
control over catalytically essential loop motions might—in contrast
with a system that competitively inhibits the active site—exhibit a
modulatory effect that is independent of substrate size and binding
affinity. To test the substrate dependence of PTP1BPS, we measured
its DR on pNPP, 4MUP, and a phosphorylated peptide (Fig. 1f).
The DRs for these substrates differed by <15% (Fig. 1g); this
similarity suggests that the magnitude of photocontrol is, in fact,
substrate independent.
Biophysical analysis of photocontrol. Although we designed our
chimeras to exploit conformational changes in the N-terminal
A’α helix of LOV2, the results of crystallographic and spectro-
scopic analyses of this photoswitch indicate that its N- and
C-terminal helices work together to transduce conformational
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Fig. 1 Minimally disruptive photocontrol of PTP1B. a Left: An alignment of a competitively inhibited structure of PTP1B (orange, pdb entry 2f71) and an
apo structure of PTP1B (yellow, pdb entry 3a5j) highlights an allosteric control system. Closure of the WPD loop (black) over an inhibitor orders the α7
helix; opening of the loop (light blue) hinders this ordering. Right: An alignment of the LOV2 domain from A. sativa (blue) and an N-terminal segment of the
same domain of A. thaliana (white) that is identical between the two proteins (pdb entries 2v0w and 4hhd, respectively). Two terminal α-helices (gray and
white) are stable in the dark state, but not the light state. b Design of a photoswitchable chimera. Light-induced unwinding of the A’α helix of LOV2
destabilizes the α7 helix of PTP1B, causing an allosteric conformational change that inhibits catalysis. We attached the C-terminal α7 helix of PTP1B to the
N-terminal A’α helix of LOV2 at crossover points in a primary sequence alignment (1–8). These points are highlighted in blue (PTP1B) and red (LOV2) in
(a). c Assays on 4-methylumbelliferyl phosphate (4MUP) show the results of chimera optimization. Construct 7 has the largest dynamic range (DR) of the
crossover variants; 7.1 has a higher activity than 7, and 7.1(T406A), termed PTP1BPS, has a larger DR than 7.1. The dashed gray and blue lines denote values
for 7.1 and 7.1(T406A), respectively. The plotted data depict the mean, SE, and associated estimates of DR for n= 6 independent experiments. d Aligned
catalytic domains of PTP1B in three structures: photoswitchable (6ntp), apo (3a5j), and competitively inhibited (2f71, α6 and α7 only). e An analysis of the
activity of PTP1BPS on p-nitrophenyl-phosphate (pNPP) indicates that light affects kcat, but not Km (kcat-dark/kcat-light= 2.50 ± 0.04). Error bars denote SE for
n= 3 independent reactions. f The DR of PTP1BPS is similar for substrates of different sizes. The plotted data depict the mean, SE, and associated estimates
of DR for n≥ 3 independent reactions. g Structures of pNPP, 4MUP, and a peptide (PEP) derived from epidermal growth factor receptor (EGFR). Source
data are provided as a Source Data file.
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changes across the protein23,31. To examine the contribution of
both helices to the photoresponse of chimera 7.1, one of our most
light-sensitive chimeras, we introduced disruptive mutations (i.e.,
we added charged residues at buried sites31,32). For both helices,
disruptive mutations reduced light-dependent catalytic activity as
effectively as C450M, a “dark state” mutation that prevents the
formation of the cysteine adduct in LOV2; complete removal of
the Jα helix had the same effect (Fig. 2a). Our results thus indicate
that both A’α and Jα helices are necessary for LOV2-mediated
control of PTP1B activity.
A previous NMR study of PTP1B dynamics showed that
mutations in its L11 loop can disrupt allosteric communication
between the α7 helix and WPD loop29. To confirm the
contribution of allostery to photocontrol, we modified chimera
7.1 with a mutation known to exert such an effect: Y152A/Y153A.
This modification reduced DR by ~25%, a disruption distinct
from the conservative/beneficial effects of alanine substitutions in
the α7 helix (Fig. 2a). The sensitivity of DR to mutations in the
L11 loop indicates that the native allosteric network of PTP1B is,
indeed, necessary for optogenetic control of its catalytic activity.
We hypothesized that our most photoswitchable chimeras
might exhibit large changes in secondary structure between light
and dark states—changes that result largely from ordered-to-
disordered transitions of the A’α, Jα, and α7 helices. To test
this hypothesis, we used circular dichroism (CD) spectroscopy
to compare optically induced shifts in α-helical content
(δ222= [CD222-dark−CD222-light]/CD222-dark; Fig. 2b). Intriguingly,
changes were large for the chimeras with light-dependent
catalytic activities but spanned a range of values for low-DR
constructs (Fig. 2c). The one-way dependence of DR on δ222
indicates that changes in α-helical conformation are necessary,
but not sufficient for photocontrol.
We speculated that chimeras with large changes in α-helical
content (δ222) but light-insensitive catalytic activities (low DRs)
might suffer from weak conformational coupling between the
LOV2 and PTP1B domains. To study this coupling, we carried
out two experiments. In the first, we examined the thermal
recovery of LOV2 from the light state by illuminating PTP1B-
LOV2 chimeras with blue light and, subsequently, measuring the
return of α-helical content in the dark (Fig. 2d). A link between
the conformation of LOV2 and α-helical content is supported by
(i) the sensitivity of δ222 to disruptive mutations in LOV2 and (ii)
the insensitivity of δ222 to the catalytic response of PTP1B
(that is, activity-modulating structural changes in PTP1B, which
presumably differ between high- and low-DR chimeras, do not
affect δ222). In the second experiment, we examined the thermal
recovery of PTP1B by measuring the return of tryptophan
fluorescence in the dark (Fig. 2e). A link between the
conformation of PTP1B and tryptophan fluorescence is sup-
ported by (i) the existence of six tryptophan residues in PTP1B
(Fig. 2f) and (ii) the insensitivity of recovery kinetics to the
removal of W491, the only tryptophan in LOV2 (Fig. 2g).
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Fig. 2 Analysis of allosteric communication in PTP1BPS. a Mutations that either prevent adduct formation in LOV2 (C450M), destabilize the A’α and Jα
helices (I532E, I539E, and ΔJα), or disrupt the allosteric network of PTP1B (Y152A/Y153A) reduce the photosensitivity of 7.1 and, with the exception of I532E
and C450M, lower its specific activity. The plotted data depict the mean, SE, and associated estimates of DR for n= 6 independent experiments. b Exposure of
PTP1BPS to 455 nm light reduces its α-helical content (i.e., the mean residue ellipticity [MRE] at 222 nm). c An analysis of different chimeras indicates that
light-induced changes in α-helical content (i.e., δ222= [CD222-dark−CD222-light]/CD222-dark, or the fractional change in MRE at 222 nm) are necessary, but not
sufficient for light-sensitive catalytic activity (i.e., high DR). Mutations correspond to variants of 7.1. Chimeras with large values of δ222 appear in blue; the
dashed line indicates δ222 for equimolar amounts of free PTP1B and LOV2. Error bars denote SE for n= 6 independent reactions. d, e Thermal recovery of (d)
α-helical content (i.e., the change in MRE at 222 nm normalized by the full change over 250 s) and (e) tryptophan fluorescence (i.e., the change in fluorescence
normalized by the full change over 250 s) of PTP1BPS. f A crystal structure of PTP1B (pdb entry 2f71) shows the locations of six tryptophan residues (blue) and
the WPD loop (black). g Kinetic constants for thermal recovery are larger for α-helical content than for tryptophan fluorescence (the latter of which is not
affected by W491; *, unmeasurable). The discrepancy between these constants is smallest for PTP1BPS (i.e., 7.1(T406A)). The plotted data depict the mean,
associated data points, and SE for n= 6 independent reactions. Source data are provided as a Source Data file.
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Intriguingly, kinetic constants for thermal recovery were higher for
α-helical content than for tryptophan fluorescence, an indication
that LOV2 reverts to its dark state more quickly than PTP1B.
This discrepancy was (i) smallest for PTP1BPS, the highest-DR
construct, (ii) moderate for 7.1(G528A/N538E), a construct with an
intermediary DR, and (iii) largest for 7.1(I532E), a Jα-destabilized
mutant without light-dependent catalytic activity (Fig. 2g). This
pattern in recovery kinetics provides direct evidence that strong
interdomain conformational coupling is necessary for photocontrol
of PTP1B activity.
Preparation of a natively localized variant of PTP1BPS. Inside
the cell, PTP1B possesses a C-terminal region—a disordered
proline-rich domain followed by a short membrane anchor—that
localizes it to the endoplasmic reticulum (ER; Fig. 3a)33. To
examine the influence of this region on photocontrol, we attached
the bulk of it (all but the hydrophobic ER anchor) to the C-
terminus of PTP1BPS and assayed the extended chimera in vitro.
This construct (PTP1BPS*) exhibited a reduced DR, which was
not improved by the addition of stabilizing mutations to the Jα
helix (Figs. 3b, c); nonetheless, it remained photoswitchable. A
construct with the full-length C-terminus of PTP1B (everything
including the ER anchor; PTP1BPS**), in turn, conferred native
localization in COS-7 cells (Fig. 3d).
We completed our characterization of the elongated forms of
PTP1BPS by examining the influence of LOV2 on interactions
mediated by the disordered C-terminal region. Briefly, we
compared the susceptibilities of PTP1B1-405 and PTP1BPS* to
inhibition by DPM-1001, an inhibitor that binds preferentially
to this region (Supplementary Fig. 5)34. To our surprise, IC50’s
differed by ~30%; this small difference indicates that LOV2 does
not preclude regulatory interactions with the disordered region.
Importantly, DPM-1001 also binds weakly to the catalytic
domain, likely by binding near the α7 helix35; IC50’s for
PTP1B1-321 and PTP1BPS were, thus, much higher than IC50’s
for the full-length constructs and exhibited a greater sensitivity
to LOV2. This finding suggests that LOV2 may affect weak
interactions that occur at its point of attachment (though, this
region is not an established target for post-translational
modifications).
An optogenetic probe for studying intracellular signaling. To
examine the function of PTP1B-LOV2 chimeras in living cells, we
sought a genetically encodable sensor for PTP1B activity. Several
previously developed sensors for PTKs could plausibly support
such a function; we chose a sensor for Src kinase36, an enzyme
with an orthogonal activity to PTP1B37. This biosensor consists
of an SH2 domain, a flexible linker, and a substrate domain (i.e.,
WMEDYDYVHLQG, a peptide derived from p130cas), all
sandwiched between two fluorescent proteins (FPs). Src-mediated
phosphorylation of the substrate domain causes it to bind to the
SH2 domain, reducing Förster resonance energy transfer between
the FPs (FRET; Fig. 4a); PTP1B-mediated dephosphorylation of
the substrate domain, in turn, reverses this effect and increases
FRET. To enhance the compatibility of the sensor with the blue
light necessary to stimulate LOV2, we replaced CFP and YPet—
the original FPs—with mClover3 and mRuby3, which have longer
excitation wavelengths38. As expected, incubation of the modified
sensor with Src reduced FRET and increased the donor/acceptor
emission ratio; simultaneous incubation with Src and PTP1B
(or Src and EDTA), by contrast, prevented this increase (Fig. 4b).
We began our imaging studies by co-expressing the biosensor
with PTP1B-LOV2 chimeras in COS-7 cells. These cells are large
and flat and, thus, facilitate imaging of subcellular regions39;
previous studies have used them to examine PTP1B-mediated
signaling events40,41. Whole-cell irradiation of cells expressing
PTP1BPS with 457 nm light increased the biosensor signal in both
the nucleus and cytosol by ~7%, a change larger than the 3–4%
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increase afforded by the dark-state mutant (Fig. 4c and
Supplementary Fig. 6); the response of the biosensor in cells
expressing PTP1BPS**, by contrast, was nearly imperceptible when
compared with the dark-state analog (Supplementary Fig. 7).
We note: Our imaging experiments rely on basal Src activity (i.e.,
we do not overexpress this enzyme). Accordingly, our findings
indicate that transient inactivation of PTP1B allows background
concentrations of Src to effect a rapid increase in the population
of phosphorylated biosensor (other kinases could certainly
contribute to this response, but our chosen biosensor is fairly
specific for Src42).
Local irradiation of photoswitchable enzymes can permit
detailed studies of spatially dependent signaling events and, by
minimizing cellular exposure to optical stimuli, reduce the
background signal caused by photobleaching10. To assess the
compatibility of our light-sensitive chimeras with spatiotemporal
studies, we used 405-nm light to irradiate 5-µm circular regions
within COS-7 cells, and we measured the response of the
biosensor (Figs. 4d, e). In cells expressing PTP1BPS, local
irradiation of the cytosol produced a transient spike in donor/
acceptor emission ratio within the irradiated region and a modest,
smooth increase in signal within a secondary region located far
from the first (Fig. 4e and Supplementary Fig. 8); both irradiated
and secondary regions maintained a similar increase in signal for
at least 30 s after irradiation. In cells expressing PTP1BPS**,
irradiation near the nucleus produced a similar change in signal,
while irradiation near the plasma membrane (PM) failed to do so
(Fig. 4e and Supplementary Figs. 9–11a). In all cases, dark-state
mutants produced no detectable effect. Our results thus indicate
that localized inactivation of PTP1BPS and nucleus-proximal
PTP1BPS** can produce a measurable cell-wide increase in the
phosphorylation state of their targets.
The ER is a vesicular network that extends unevenly from the
nucleus of the cell. To determine if the reduced activity of
PTP1BPS** near the PM results from the low abundance of ER in
this region, we used BFP-Sec61β, a genetically encoded ER
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label43, to measure the subcellular distribution of ER. The
fluorescence of 5-µm circular regions located near the PM
was 2.7-fold lower than the fluorescence of equivalently sized
regions located near the nucleus (Supplementary Figs. 11b, c);
this discrepancy suggests that the diffuse distribution of
PTP1BPS** near the PM limits its activity on membrane-
proximal targets.
Cells rely on complex networks of biomolecular interactions to
transmit, filter, and integrate chemical signals44. The biochemical
repercussions of changes in the activity of any single regulatory
enzyme are, thus, difficult to assess with artificial biosensors alone.
To evaluate the influence of modest changes in PTP1B activity on
the phosphorylation state of a native regulatory target, we generated
HEK293T/17 cells that stably express PTP1BPS** and used an
enzyme-linked immunosorbent assay (ELISA) to measure shifts
in IR phosphorylation caused by transient illumination (455 nm,
10min). To our surprise, illumination increased IR phosphorylation
to levels that rivaled those elicited by high concentrations of both an
allosteric inhibitor (BBR) and insulin (Fig. 4g). These optically
derived shifts—which, by our best estimate, exceed a 20-fold
increase over background levels (Supplementary Note 2)—did not
occur in cells shielded from light or in cells stably expressing
PTP1BPS**(C450M); IR phosphorylation levels in these two varieties
of cells were indistinguishable from those of the wild-type cell line.
Our findings thus suggest that PTP1BPS** leaves native phosphor-
ylation levels intact but enables large shifts in target phosphoryla-
tion under blue light.
Discussion
The study of PTPs has long suffered from a paucity of tools for
probing and measuring their intracellular activities45. In this
study, we developed a photoswitchable variant of PTP1B and
used it to exert spatiotemporal control over the phosphorylation
state of a genetically encoded biosensor in living cells. Transient
irradiation of the full-length, natively localized construct near
the nucleus but not the PM produced cell-wide changes in
sensor phosphorylation. Importantly, the allosteric photo-
control system afforded shifts in activity that reach—by our best
estimate—70–85% of the maximum achievable dynamic range
and match physiologically influential shifts in activity caused by
post-translational modifications of PTP1B that occur outside of
its active site (Supplementary Table 1). Our analysis of IR
phosphorylation, in turn, suggests that modest changes in the
activity of PTP1B are sufficient to effect large changes (i.e., over
20-fold) in the phosphorylated fraction of its regulatory targets.
This result, which evidences an intriguing sort of hypersensi-
tivity, indicates that the photoswitchable variant of PTP1B—
which unlike PTP inhibitors46, offers both exquisite selectivity
and spatiotemporal precision—could provide a useful tool
for biochemical analyses that rely on precise, protein-specific
perturbations (e.g., imaging studies and proteomic analyses)47.
Broadly, PTP1B is a therapeutic target for the treatment of dia-
betes, obesity48, breast cancer49, and cardiovascular disease50,
and has emerged as a potential modulator of inflammation51,
anxiety52, immunity53, memory54, and neural specification in
embryonic stem cells55; by facilitating detailed analyses of the
contribution of PTP1B to these complex processes, the tools
developed in this study could help to elucidate the biochemical
basis—and perhaps, shared origin—of a diverse set of physiolo-
gical states.
Classical—or tyrosine-specific—PTPs possess several features
that are particularly incompatible with conventional approaches
to optical control: Their solvent-exposed active sites are distal to
both termini and, thus, difficult to obstruct with light-sensitive
fusion partners56; they engage in protein–protein interactions at
delocalized—and incompletely mapped—surface sites that make
the physiological repercussions of domain insertion (or domain
dissection) difficult to assess57–59; and their subcellular localiza-
tion affects regulatory function in a non-binary manner that
complicates the use of optically induced re-localization to study
cell signaling40,60. Accordingly, future efforts to use these meth-
ods to build photoswitchable PTPs (perhaps, with higher DRs
than the constructs described in this study) could be worthwhile;
accompanying analyses of the influence of new control systems
on protein structure, activity, and/or subcellular localization,
however, will facilitate a detailed assessment of their benefits over
the present system.
The results of this work offer two general insights for the
design of genetically encoded probes. First, kinetic assays of
PTP1BPS demonstrate that allosteric systems for photocontrol can
—at least, within some classes of proteins—effect isolated changes
in kcat; such designs may be less disruptive to substrate binding
(i.e., more substrate agnostic) than systems in which light-
sensitive domains act as competitive inhibitors (which can be
outcompeted by a sufficiently high concentrations of substrate).
Future analyses of differences in the intracellular concentrations
and binding affinities of regulatory targets will clarify the extent
of this benefit. Second, spectroscopic analyses of PTP1B-LOV2
chimeras provide experimental evidence that strong interdomain
conformational coupling can enhance allostery-derived photo-
control of one domain with another. Computational methods
to optimize this coupling (e.g., methods to identify architectures
that enhance correlated motions between fused domains or that
reduce the dissipation of energy between them) could, thus,
facilitate the development of new—and, perhaps, protein-specific
—varieties of minimally disruptive control systems.
Methods
Cloning and molecular biology. We constructed PTP1B-LOV2 chimeras by fusing
PTP1B and LOV2 at crossover points in a primary sequence alignment. In brief, we
used EMBOSS Needle, an implementation of the Needleman-Wunsch algorithm61,
to align the C-terminus of PTP1B (residues 285–305) with the N-terminus of
LOV2 (residues 387–410), and we selected eight matching aligned residues as
fusion points for the two domains (Fig. 1b). To assemble chimeric genes, we
amplified DNA encoding PTP1B and LOV2 from pET21b and pTriEx-PA-Rac1
plasmids, respectively. (The pET21b plasmid was a kind gift from the Tonks Group
of Cold Spring Harbor Laboratory; we purchased pTriEx-PA-Rac1 from Addgene.)
We joined the two amplified segments with overlap extension PCR (oePCR; see
Supplementary Table 3 for primers) and ligated the final chimeric product into
pET16b for protein expression.
We generated additional constructs with standard techniques. To build single-
site mutants and truncation variants, we amplified parent plasmids with
appropriate mutagenic primers (Supplementary Table 4). To construct PTP1BPS*
and PTP1BPS**, we amplified C-terminal regions of PTP1B (residues 299–405 and
299–435, respectively) from pGEX-2T-PTP1B (Addgene) and used Gibson
assembly to join them to the C-terminus of PTP1BPS (50 °C for 1 h; see
Supplementary Table 5 for primers). Finally, to construct GFP-tagged versions of
PTP1BPS, PTP1BPS**, and PTP1B435, we amplified these genes from their parent
plasmids (see Supplementary Table 5 for primers) and ligated the PCR product
into pAcGFP1-C1 (Clonetech, Inc.) at the NcoI and BamHI sites of the MCS for
protein expression.
We developed a biosensor for PTP1B by replacing the fluorescent proteins of a
biosensor for Src kinase36 with mClover3 and mRuby338. In brief, we amplified
DNA encoding the following components: (i) the central segment of the Src
biosensor—the SH2 domain, interdomain linker, and substrate domain (i.e.,
WMEDYDYVHLQG, a peptide derived from p130cas)—from its parent plasmid
(a Kras-Src FRET biosensor, Addgene), (ii) genes for mClover3 and mRuby3
(plasmids pNCS-mClover3 and pNCS-mRuby3, respectively), and (iii) the
backbone of pAcGFP1-C1 (Clonetech, Inc.). After amplification, we joined all
segments with Gibson assembly (50 °C for 1 h; see Supplementary Table 6 for
primers).
For live-cell studies, we integrated the modified biosensor and PTP1B-LOV2
chimeras into pAcGFP1-C1 by using protocols described above. In short, we
amplified DNA encoding (i) PTP1BPS or PTP1BPS**, (ii) a ribosomal skipping
peptide sequence (P2A-GSG, GSGATNFSLLKQAGDVEENPGP), (iii) the
modified biosensor, and (iv) the pAcGFP1-C1 backbone, and we joined the
segments with Gibson assembly (50 °C for 1 h; see Supplementary Tables 6 and 7
for primers and DNA fragments, respectively).
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Protein expression and purification. We overexpressed PTP1B1-281, PTP1B1-321,
PTP1B1-405, LOV2404-547-, PTP-LOV2 chimeras, Src251-536, and the modified bio-
sensor in E. coli by carrying out the following steps: (i) We subcloned 6x
polyhistidine-tagged versions of each construct into a pET16b plasmid. We posi-
tioned the tag at the N-terminus of Src and the FRET-based biosensor and the
C-terminus for all other proteins. For Src, we also added a gene for Cdc37, a
chaperone that facilitates protein folding in bacteria62. (ii) We transformed E. coli
BL21(DE3) cells (New England Biolabs C2527) with each plasmid and spread the
transformed cells onto an agar plate (25 g/L LB, 100 mg/L carbenicillin, 1.5% agar).
(iii) We used one colony from each plate to inoculate a 20-mL culture (25 g/L LB
and 100mg/L carbenicillin), which we incubated in a shaker at 37 °C overnight. (iv)
We used the overnight culture to inoculate 1 L of induction media (20 g/L tryptone,
10 g/L yeast extract, 5 g/L NaCl, 4 g/L M9 slats, 4 g/L glucose, and 100 mg/L car-
benicillin), which we incubated in a shaker at 37 °C until it reached an OD600 of
~0.6. (v) We induced protein expression by adding 100 μL of 1M solution of
isopropyl β-D-1-thiogalactopyranoside (IPTG) to each culture and by reducing the
temperature to 22 °C. (vi) At 7 h, we pelleted cells (3950 × g, 20 min; JA-10
Beckman Coulter).
We purified all proteins with fast protein liquid chromatography. To begin, we
lysed cell pellets by adding the following components to each gram of pellet: 4 mL
of B-PER (Thermo Fisher Scientific, Inc.), 1 mg MgSO4, 2 mg Nα-p-Tosyl-L-
arginine methyl ester hydrochloride, 1.25 mg tris(2-carboxyethyl)phosphine
(TCEP), 3.75 µl phenylmethylsulfonyl fluoride, 1 mg Lysozyme, and 10 µl DNase.
After mixing to homogeneity, we rocked the lysis mixtures for 1 h at room
temperature (~22 °C), pelleted the cell debris (3950 × g, 60 min), and isolated the
supernatant. To clarify the supernatant further, we added a saturated solution of
ammonium sulfate to 10% (v/v), pelleted the resulting mixture (3950 × g, 15 min),
and used a 0.22-μm filter to remove particulates. To begin purification, we
exchanged the filtered supernatant into Tris-HCl buffer (50 mM Tris-HCl, 0.5 mM
TCEP, pH 7.5), flowed the exchanged solution over an Ni column, and eluted the
protein of interest with a 0–100% gradient of imidazole (50 mM Tris-HCl, 0.5 mM
TCEP, 500 mM imidazole, pH 7.5). For further purification, we exchanged each
protein into HEPES buffer (50 mM HEPES, 0.5 mM TCEP, pH 7.5), flowed the
exchanged solution over an anion exchange column, and eluted the final protein
with 0–100% gradient of NaCl (50 mM HEPES, 0.5 mM TCEP, 500 mM NaCl, pH
7.5). We purchased all columns (26/10 HiPrep [desalting], HisTrap HP [Ni], and
HiPrep Q HP 16/10 [anion exchange]) from GE Healthcare, Inc. We confirmed the
purity of final solutions with SDS-PAGE, and we stored each protein in storage
buffer (50 mM HEPES, 0.5 mM TCEP, 20 v/v% glycerol, pH 7.5) at −80 °C.
Initial analysis of photoswitching. We screened PTP-LOV2 chimeras for light-
dependent catalytic activity by measuring their activity on 4MUP in the presence
and absence of light. In brief, we carried out the following steps: (i) In a room
illuminated with a red light (625 nm), we prepared two 96-well plates—hereafter
referred to as the “light plate” and “dark plate”—with 100-μL reactions consisting
of buffer (50 mM HEPES, 0.5 mM TCEP, pH 7.5), substrate (500 μM 4MUP), and
enzyme (5 nM); we added a plastic cover to each plate. (ii) We encased the dark
plate in foil and placed the light plate in a chamber made up of two opposing
reflective steel bowls fed with a 455-nm light (~450 mW, SLS-0301-C, Mightex
Systems, Inc.; Supplementary Figs. 1d–f). (iii) We incubated both plates at room
temperature (~22 °C). (iv) At 7, 14, 21, 28, 35, and 42 min after beginning the
reaction, we removed each plate from its resting position (i.e., the foil cover or light
chamber), loaded it into a SpectraMax M2 plate reader, and measured the for-
mation of 4-methylumbelliferone (365ex/450em); we immediately returned each
plate to its resting position. (v) We used discrete measurements to estimate initial
rates and, thus, to calculate DR (i.e., Vo-dark/Vo-light).
We minimized error in our measurements of photoswitching with four
precautions: (i) We used concentrations of enzyme and substrate that sustained
initial reaction rates for 42 min, a length of time that minimizes the disruption of
1-min breaks required to measure product formation. (ii) For each construct in
each plate, we prepared two sets of three compositionally identical, yet differentially
positioned wells; this arrangement minimizes potential contributions from
nonuniform illumination. (iii) For each construct at each illumination condition,
we repeated the assay at least three times, collecting a total six estimates of initial
rate, each based on measurements from three wells. (iv) We established a control
range: When wild-type PTP1B, which was present in each plate, exhibited a 10%
difference in activity between the two plates, we discarded data from both (i.e., we
assumed that differences in activity between the two plates were not caused by the
presence or absence of light).
We examined the light-dependent catalytic activity of PTP1BPS on a
phosphopeptide (DADEpYLIPQQG from EGFR) by following the aforementioned
procedure with several differences: (i) We used a substrate concentration of 120 µM
and a total reaction volume of 40 μL. (ii) We added malachite green solution
(Sigma-Aldrich) to stop individual reactions at 2, 4, 6, or 8 min. (iii) We measured
the formation of phosphate by using the plate reader to quantify a complex formed
between orthophosphate, molybdate, and Malachite Green (620abs); we waited until
the end of our experiments (i.e., 8 min) for all absorbance measurements. We note:
the statistically indistinguishable DRs (p < 0.01, two-tailed Student’s t test)
determined for PTP1BPS on substrates that require different spectrophotometric
measurements (i.e., fluorescence at 450 nm for 4MUP and absorbance at 620 nm
for a phosphopeptide) suggest that the illumination conditions used for optical
measurement do not artificially depress or enhance DR.
Enzyme kinetics. We examined the influence of photomodulation on enzyme
kinetics by measuring the activities of PTP1BPS and PTP1BPS* on pNPP in the
presence and absence of light (i.e., we used dark and light plates as described
above). Briefly, we prepared 100-μL reactions consisting of buffer (50 mM HEPES,
0.5 mM TCEP, pH 7.5), substrate (0.2, 0.5, 1, 2.5, 5, 10, and 15 mM pNPP), and
enzyme (25 nM); at 4, 8, 12, 16, and 20 min after initiating the reaction, we
measured the production of p-nitrophenol (405abs) on a SpectraMax M2 plate
reader; and we used DataGraph to fit initial rates to a Michaelis–Menten model of
enzyme kinetics. Final values of kcat and Km reflect the mean of independent
estimates determined from three Michaelis–Menten curves; error kcat and Km
reflects the standard error of those estimates.
We examined the inhibitory effect of DPM-1001 on PTP1B-mediated
hydrolysis of pNPP as follows: (i) We carried out the aforementioned pNPP
reactions in the presence of different concentrations of DPM-1001 (0, 20, 40, 60 μM
for PTP1B1-405 and PTP1BPS*; 0, 100, 200, 400 μM for PTP1B321 and PTP1BPS).
(ii) We used MATLAB’s “nlinfit” and “fminsearch” functions to fit (a) initial-rate
measurements collected in the absence of inhibitors to a Michaelis–Menten model
and (b) initial-rate measurements collected in the presence and absence of inhibitors
to four models of inhibition (i.e., competitive, noncompetitive, uncompetitive, and
mixed inhibition63). (iii) We used an F-test to compare the fits to (a) a mixed model,
which has two parameters, and (b) each nested single-parameter model with the
lowest sum of squared errors for a given dataset. DPM-1001 exhibited mixed
inhibition for all constructs (p < 0.01, two-tailed Student’s t test). (iv) We estimated
IC50’s by using the best-fit kinetic model to determine the inhibitor concentration
required to reduce initial rates by 50% on 15mM pNPP. This high substrate
concentration minimizes the concentration dependence of IC50’s. We used the
MATLAB function “nlparci” to determine the confidence intervals of kinetic
parameters and propagated those intervals to estimate the corresponding confidence
on IC50’s.
We compared the activities of PTP1B1-281 and PTP1B1-321 on pNPP by using a
continuous assay. Briefly, we prepared 100-μL reactions consisting of buffer
(50 mM HEPES, 0.5 mM TCEP, pH 7.5), pNPP (0.2, 0.5, 1, 2.5, 5, 10, and 15 mM),
and enzyme (25 nM); we measured the production of p-nitrophenol at 5-s intervals
for 270 s (SpectraMax M2 plate reader); we used DataGraph to fit initial rates to a
Michaelis–Menten model. Final values of kcat and Km reflect the mean of
independent estimates determined from three Michaelis–Menten curves; error kcat
and Km reflects the standard error of those estimates.
Finally, we evaluated the reversibility of our LOV2-based light switch by
illuminating 25 μM of PTP1BPS (50 mM HEPES, 0.5 mM TCEP, pH 7.5) for 10 s
and by, subsequently, monitoring its activity on 5 mM pNPP after 5 min in the
dark. To minimize error, we repeated this experiment three times with seven cycles
per experiment (Supplementary Fig. 2).
X-ray crystallography. We prepared crystals of PTP1BPS by using hanging drop
vapor diffusion. To begin, we prepared a concentrated solution of PTP1BPS
(~400 μM PTP1BPS, 50 mM HEPES, pH 7.3) and a crystallization solution
(100 mM HEPES, 200 mM magnesium acetate, and 14% polyethylene glycol 8000,
pH 7.5); we mixed the two solutions in 1:2, 1:3, and 1:6 ratios (protein: crystal-
lization) to form 7–9 μl droplets for crystal growth; and we incubated the droplets
over reservoirs filled with crystallization solution at 4 °C in the dark. Long hex-
agonal crystals with a yellow hue appeared after 1–3 weeks. Prior to freezing, we
soaked all crystals in cryoprotectant (100 mM HEPES, 200 mM magnesium acetate,
and 25% polyethylene glycol 8000, pH 7.5) overnight.
We collected X-ray diffraction through the Collaborative Crystallography
Program of the Berkeley Center for Structural Biology. We performed integration,
scaling, and merging of XRD data with the xia2 software package, and we carried
out molecular replacement with the Phenix graphical user interface, followed by
one round of PDB-REDO64. The crystallographic data collected in this study are
reported in Table 1.
Circular dichroism spectroscopy. We examined the influence of photomodula-
tion on the secondary structure of PTP1B-LOV2 chimeras by using a circular
dichroism spectrophotometer (Applied Photophysics Chirascan Plus) to measure
optically induced changes in α-helical content. To collect full-spectrum measure-
ments, we incubated 0.2 g/L solutions of each chimera (10 mM NaPi, 0.5 mM
TCEP, pH 7.5) in a crystal cuvette (0.05-cm path length) for 10 s with/without blue
light (455 nm) and immediately measured mean residue ellipticity (MRE) at 1-nm
increments from 185 to 260 nm. To measure thermal recovery, we began as before,
but we measured MRE at 222 nm every 2.5 s for 250 s in the dark. We normalized
the CD data thus gathered with Eq. (1), where CDt, CD0, CD250 represent MRE at t,
0, and 250 s, respectively; and we fit the normalized data to an equation for
exponential decay (Eq. (2)). Final values of k reflect the mean and standard error of
values determined from fits to six data sets.
ΔCDn ¼
CDt  CD0
CD250  CD0
ð1Þ
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ΔCDn ¼ ekt ð2Þ
Fluorescence spectroscopy. To examine the influence of photomodulation on the
conformation of PTP1B within PTP1B-LOV2 chimeras, we use fluorescence
spectroscopy to measure optically induced changes in tryptophan fluorescence. In
brief, we prepared 60 µM solutions of protein (50 mM HEPES, 0.5 mM TCEP, pH
7.5) in a Helma ultra-micro quartz cuvette (Thomas Scientific, Inc.); we illuminated
those solutions for 10 s with a 455-nm light; and we monitored fluorescence (280ex/
365em) in 10-s intervals for 200 s using a SpectraMax M2 plate reader. We nor-
malized the fluorescence data, thus gathered, with Eq. (3), where Wt, W0,
Wn ¼
Wt W0
W250 W0
ð3Þ
Wn ¼ ekt ð4Þ
W250 represent the emission at t, 0, and 250 s, respectively; and we fit the nor-
malized data to an equation for exponential decay (Eq. (4)). Final values of k reflect
the mean and standard error of values determined from fits to six datasets.
Biosensor development. We assessed the sensitivity of an Src biosensor36 to the
activity of PTP1B by incubating it with Src in the presence and absence of PTP1B.
We prepared 100-μL reactions consisting of 2 µM biosensor and 300 nM Src kinase
in 1X kinase buffer A (Thermo Fisher Scientific, Inc.) supplemented with 2 mM
DTT, 2 mM MgCl2, and 50 µM ATP. For a subset of reactions, we added PTP1B
and EDTA at concentrations of 100 nM and 50mM, respectively. For each reac-
tion, we monitored the fluorescence of mClover3 (475ex/520em) and mRuby3
(475ex/600em nm) in 10-min increments for 300 min on a Spectramax M2 plate
reader.
Preparation of cells for imaging experiments. For live-cell imaging experiments,
we grew COS-7 cells (ATCC CRL-1651, seeded from a freezer stock) in DMEM
media supplemented with 10% FBS, 100 units/ml penicillin, and 100 units/ml
streptomycin for ~24 h to achieve 70–90% confluency, and we seeded them on a
20-mm glass-bottom cell culture dish (MatTek). At 10–20 h after seeding, we
depleted endogenous PTP1B by transfecting the cells with 25 nM of a PTP1B
siRNA silencer (AM16794, Thermo Fisher Scientific, Inc.), 12.5 μl Dharmafect, and
10% FBS. At 5 h after adding siRNA, we washed cells with 1X PBS buffer, replaced
this buffer with DMEM media supplemented as above (with FBS and antibiotic),
and transfected the cells with 2000 ng of plasmid DNA and 6 μl of Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s protocols. At 10–12 h
after transfection with plasmid DNA, we imaged the cells in Opti-MEM media
at 37 °C.
Confocal microscopy. We carried out all imaging experiments with a ×100 1.45
NA oil objective on a Nikon A1R confocal scanning microscope supplemented
with an environmental chamber (37 °C, 75% humidity, and 5% CO2; Pathology
Devices, Inc.). To localize both GFP-tagged PTP1B-LOV2 chimeras and BFP-
Sec61β, we illuminated Cos-7 cells with a 488-nm laser (0.57 mW/μm2 with a pixel
dwell time of 2.2 µs) and imaged them with a 525/50 nm bandpass filter. The
plasmid bearing BFP-Sec61β (pTagBFP-C1) was a kind gift from the lab of Gia
Voeltz of the University of Colorado, Boulder.
For whole-cell activation studies, we illuminated individual cells with a 457-nm
laser focused over the breadth of the cell (0.14 mW/μm2 with a pixel dwell time of
4.8 µs). To examine the photoresponse of the biosensor after activation, we
illuminated the field of view with a 488 nm laser (0.57 mW/μm2) and imaged the
entire cell with 525/50 nm and 600/50 nm bandpass filters for 1 min (resonant
scanning mode with 518.1-ms frame time). We estimated the average change in
donor/acceptor emission ratio between 0 and 60 s after activation by calculating the
interquartile average of measurements from 11 individual cells.
For localized activation studies, we focused 405-nm light over 5-µm circular
regions (0.49 mW/μm2 with a pixel dwell time of 4.8 µs) and imaged the
photoresponse of the biosensor by illuminating at 488 nm (0.57 mW/μm2; 480/
30 nm excitation filter) and imaging with 525/50 nm and 600/50 nm bandpass
filters for 1 min. We estimated the average change in donor/acceptor emission ratio
within circular regions, in turn, by calculating the difference in 5-s averages starting
(i) 5 s before activation and (ii) 35 s after activation; final estimates of changes in
donor/acceptor emission reflect the mean and standard error from six independent
measurements (i.e., six individual cells).
The 488-nm light used to image our FRET-based biosensor could plausibly
stimulate LOV2, which absorbs at 488 nm (although less so than at 405 and
457 nm)65. The results of Fig. 4e, however, indicate that such activation does not
occur. In brief, irradiation with 405-nm light causes a transient increase in FRET
signal for cells expressing PTP1BPS and PTP1BPS**, but not for cells expressing
light-insensitive analogs of these two constructs; accordingly, 488-nm light does
not activate LOV2 (at least, no fully) under our imaging conditions (if it did so,
irradiation at 405 nm would not elicit further activation). The insensitivity of LOV2
to 488-nm light likely results from both (i) the low extinction coefficient of LOV2
at 488 nm and (ii) the insufficient combination of power and pixel dwell time of the
488-nm laser.
Preparation of cells for ELISA. We prepared HEK293T/17 cells (ATCC CRL-
11268) stably expressing PTP1BPS** or PTP1BPS(C450M) by following standard
protocols. In brief, we grew the cells in 75 cm2 culture flasks (Corning)
with DMEM media supplemented with 10% FBS, 100 units/ml penicillin, and
100 units/ml streptomycin. When cells achieved 60–80% confluency, we trans-
fected them with (i) 2000 ng of plasmid DNA (pAcGFP1-C1 with PTP1BPS** or
PTP1BPS**(C450M), but no GFP) linearized with the ApaLI restriction enzyme
(New England Biolabs) and (ii) 6 μl of Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s protocols. We passaged the cells in our growth
media (as above) supplemented with 1.5 µg/mL puromycin, and we replaced the
media every day for 10 days. We passaged the cells seven times before freezing
them for further use.
ELISA of insulin receptor phosphorylation. We examined IR phosphorylation in
HEK293T/17 cells exposed to various conditions by using an enzyme-linked
immunosorbent assay (ELISA). To begin, we used siRNA to deplete cells stably
expressing PTP1BPS** or PTP1BPS** (C450M) of endogenous PTP1B (see above)
and starved all cells for 48 h with FBS-free media. After starvation, we exposed cells
to one of several conditions for 10 min: (i) 455-nm light (we irradiated the culture
flask with ~450 mW light, SLS-0301-C, Mightex Systems, Inc.), (ii) sustained
darkness (i.e., we wrapped the culture flask in aluminum foil), (iii) 300 µM of BBR
(3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N-[4-[(2-thiazolylamino)sulfonyl]
phenyl]-6-benzofuransulfonamide, Cayman Chemical), an allosteric inhibitor of
PTP1B, (iv) 10 nM human insulin (Sigma), and (v) 1.5% DMSO. After these
perturbations, we incubated each sample with lysis buffer (Cell Signaling Tech-
nology) supplemented with 1X halt phosphatase inhibitor cocktail and 1X halt
protease inhibitor cocktail (Thermo Fisher Scientific) for 10 min, spun the cells
down, and measured IR phosphorylation by using the PathScan® Phospho-Insulin
Receptor β (panTyr) Sandwich ELISA Kit (Cell Signaling Technology; #7082).
We carried out the ELISA by using the manufacturer’s prescribed steps: (i) We
diluted the entirety of each lyophilized antibody—a detection antibody
(phosphotyrosine mouse detection mAb; #12982) and a secondary detection
antibody (anti-mouse IgG, HRP-linked antibody; #13304)—into 11 ml of antibody-
specific diluent (detection antibody diluent; #13339; HRP diluent; #13515). (ii) We
used lysis buffer to dilute each sample of cell lysate to 30 mg/ml total protein (based
Table 1 Data collection and refinement statistics for X-ray
crystallographic analysis of PTP1BPS.
PTP1BPS (6NTP)
Data collection
Space group P3121
Cell dimensions
a, b, c (Å) 89.254, 89.254, 105.747
α, β, γ (°) 90.000, 90.000, 120.000
Resolution (Å)a 52.87–1.89 (1.92–1.89)
Rmergea 0.071 (2.550)
Rpima 0.025 (0.893)
<I/σ(I)>a 17.2 (1.1)
CC1/2a 1.000 (0.626)
Completeness (%)a 100.0 (100.0)
Multiplicitya 9.0 (9.1)
Refinement
Resolution (Å) 44.67–1.89
No. reflections 37270
Rwork /Rfree 0.17922/0.21175
No. atoms
Protein 2351
Ligand/ion 1
Water 224
B-factors
Proteinb 21.7
Ligand/ionb 50.8
Waterb 47.4
R.m.s. deviations
Bond lengths (Å) 0.008
Bond angles (°) 1.488
aValues in parentheses are for highest-resolution shell. We examined one crystal.
bValues correspond to means of B-factors for the indicated atoms.
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on absorbance at 280 nm). (iii) We prepared 100 µL of 1X, 2X, 4X, and 8X dilutions
of lysate from each sample (1X corresponds to no dilution, 2X corresponds to a 1:1
dilution in lysis buffer and cell lysate, and so on), and incubated each 100-µL
sample in a single well of an antibody-coated 96-well plate (insulin receptor β
rabbit mAb coated microwells; #18872) at 4 °C overnight. (iv) We washed the cells
four times with 200 µL of 1X wash buffer and incubated the washed cells with
100 µL of detection antibody at 37 °C for 1 h. (v) We washed the cells four times as
before and incubated the cells with 100 µL of HRP-linked secondary antibody
solution at 37 °C for 30 min. (vi) We washed the cells four times and incubated
them with 100 µL of TMB substrate at 37 °C for 10 min. (vii) We added 100 µL
of STOP solution and measured absorbance at 450 nm using SpectraMax M2
plate reader.
Statistical analysis. We used an F-test to compare one- and two-parameter
models of inhibition to one another. For all other analyses, we determined statis-
tical significance by using a two-tailed Student’s t test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1c, 1e, 1f, 2a, 2b, 2c, 2d, 2e, 2g, 3b, 3c, 4b, 4c, 4e, and 4g
and Supplementary Figures 1b, 1c, 4a, 4c, 5b, 5c, 5d, 6b, 7b, 8c, 8d, 9c, 9d, 10c, 10d, 11a,
11c, 12a, and 12b are provided as a Source Data file; this data includes exact sample sizes
for each dataset. For clarity, Supplementary Data 1–8 also group data by type
(photoswitching experiments, kinetic analyses, FRET-based studies, etc.). The crystal
structure determined in this study is available from the RCSB Protein Data Bank (PDB
entry 6ntp). Table 1 provides the refinement statistics for this structure. Plasmids
harboring important genes used in this study are available from Addgene: LOV2
(pTriEx-PA-Rac1, #22024,) full-length PTP1B (pGEX-2T-PTP1B, #8602), and biosensor
(Kras-Src FRET biosensor, #78302). All other raw data not included in the paper are
available from the corresponding author upon request.
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